Skip to main content
SpringerLink
Log in

Cancer de l’endomètre

  • Chapter
Thérapeutique du cancer

  • 760 Accesses

Résumé

Le cancer de l’endomètre est le cancer gynécologique le plus fréquent et représente le troisième cancer féminin après le cancer du sein et le cancer colorectal [1]. Le nombre de nouveaux cas a été estimé en France en l’année 2010 à 6 563 cas soit 4,3 % de l’ensemble des cancers féminins et le nombre de décès à 1 900 [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97: 72–81

    Article  PubMed  CAS  Google Scholar 

  2. Projections de l’incidence et de la mortalité par cancer en France en 2010. http://www.invs.sante.fr/applications/cancers/projections2010/default.htm

    Google Scholar 

  3. Barakat RR, Gilewski TA, Almadrones L et al. (2000) Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 18: 3459–3463

    PubMed  CAS  Google Scholar 

  4. Greene JL, Page DL, Fleming ID et al. (2002) AJCC cancer staging manual. 6th ed. Berlin: Springer

    Google Scholar 

  5. Trope C, Kristensen GB, Abeler VM (2001) Clear-cell and papillary serous cancer: treatment options. Best Pract Res Clin Obstet Gynaecol 15: 433–446

    Article  PubMed  CAS  Google Scholar 

  6. Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ (2009) Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: nraveling a mystery. Gynecol Oncol 115: 18–25. Epub 2009 Jul 26

    Article  PubMed  Google Scholar 

  7. Baekelandt MM, Castiglione M (2009) ESMO Guidelines Working Group. Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20Suppl 4: 29–31

    PubMed  Google Scholar 

  8. Santin AD, Bellone S, Van Stedum S et al. (2005) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104: 1391–1397

    Article  PubMed  CAS  Google Scholar 

  9. Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105: 103–104

    Article  PubMed  Google Scholar 

  10. Yura Y, Tauchi K, Koshiyama M et al. (1996) Parametrial involvement in endometrial carcinomas: its incidence and correlation with other histological parameters. Gynecol Oncol 63: 114–119

    Article  PubMed  CAS  Google Scholar 

  11. Kilgore LC, Partridge EE, Alvarez RD et al. (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56: 29–33

    Article  PubMed  CAS  Google Scholar 

  12. Chuang L, Burke TW, Tornos C et al. (1995) Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes. Gynecol Oncol 58: 189–193

    Article  PubMed  CAS  Google Scholar 

  13. ASTEC study group, Kitchener H, Swart AM, Qian Q et al. (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373: 125–136

    Article  PubMed  CAS  Google Scholar 

  14. Ahmad K, Kim YH, Deppe G et al. (1989) Stage III carcinoma of the endometrium. Results of treatment. Eur J Gynaecol Oncol 10: 383–389

    PubMed  CAS  Google Scholar 

  15. Chi DS, Welshinger M, Venkatraman ES, Barakat RR (1997) The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol 67: 56–60

    Article  PubMed  CAS  Google Scholar 

  16. Baekelandt MM, Castiglione M (2008) Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19Suppl 2: 19–20

    Google Scholar 

  17. Blake P, Swart AM, Orton J et al. (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and metaanalysis. Lancet 373: 137–146

    Article  PubMed  CAS  Google Scholar 

  18. Creutzberg CL, van Putten WL, Koper PC et al. (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355: 1404–1411

    Article  PubMed  CAS  Google Scholar 

  19. Keys HM, Roberts JA, Brunetto VL, et al. (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92: 744–751

    Article  PubMed  Google Scholar 

  20. Creutzberg CL, van Putten WL, Koper PC et al. (2001) The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 51: 1246–1255

    Article  PubMed  CAS  Google Scholar 

  21. Nout RA, Smit VT, Putter et al. Portec Study group (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial. Lancet 375: 816–823

    Article  PubMed  CAS  Google Scholar 

  22. Nout RA, Putter H, Jurgenliemk-Schulz IM et al. (2009) Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 27: 3547–3556

    Article  PubMed  Google Scholar 

  23. Lian J, Mackenzie M, Joseph K et al. (2008) Assessment of extended-field radiotherapy for stage IIIC endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy. Int J Radiat Oncol Biol Phys 70: 935–943

    Article  PubMed  Google Scholar 

  24. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC et al. (2004) Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22: 1234–1241

    Article  PubMed  Google Scholar 

  25. Greven K, Winter K, Underhill K et al. (2006) Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103: 155–159

    Article  PubMed  CAS  Google Scholar 

  26. Briet JM, Hollema H, Reesink N et al. (2005) Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 96: 799–804

    Article  PubMed  Google Scholar 

  27. Fishman DA, Roberts KB, Chambers JT et al. (1996) Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 61: 189–196

    Article  PubMed  CAS  Google Scholar 

  28. Singh M, Zaino RJ, Filiaci VJ, Leslie KK (2007) Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 106: 325–333

    Article  PubMed  CAS  Google Scholar 

  29. Thigpen JT, Brady MF, Alvarez RD et al. (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736–1744

    PubMed  CAS  Google Scholar 

  30. Thigpen JT, Brady MF, Homesley HD (2001) Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19, pp. 364–367

    PubMed  CAS  Google Scholar 

  31. Whitney CW, Brunetto VL, Zaino RJ et al. (2004) Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92: 4–9

    Article  PubMed  CAS  Google Scholar 

  32. Fiorica JV, Brunetto VL, Hanjani P et al. (2004) Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92: 10–14

    Article  PubMed  CAS  Google Scholar 

  33. Ma BB, Oza A, Eisenhauer E et al. (2004) The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers—a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14: 650–658

    Article  PubMed  CAS  Google Scholar 

  34. Lhommé C, Vennin P, Callet N et al. (1999) Gynecol Oncol. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. Gynecol Oncol 75: 187–193

    Article  PubMed  Google Scholar 

  35. Martin-Hirsch PL, Lilford RJ, Jarvis GJ (1996) Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 65: 201–207

    Article  PubMed  CAS  Google Scholar 

  36. Urbaski K, Karolewski K, Kojs Z et al. (1993) Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol 14 Suppl: 98–104

    Google Scholar 

  37. Vishnevsky AS, Bokhman YaV, Loutfi G (1993) Favourable influence of adjuvant hormone therapy by oxyprogesterone caproate (OPC) and by its combination with tamoxifen on 5-year survival rate of surgical and combined treatment of primary endometrial carcinoma patients. Eur J Gynaecol Oncol 14: 150–153

    PubMed  CAS  Google Scholar 

  38. Fleming GF (2007) Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 25: 2983–2990

    Article  PubMed  CAS  Google Scholar 

  39. Thigpen JT, Blessing JA, DiSaia PJ et al. (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12: 1408–1414

    PubMed  CAS  Google Scholar 

  40. Aapro MS, van Wijk FH, Bolis G et al. (2003) European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14: 441–448

    Article  PubMed  CAS  Google Scholar 

  41. Thigpen JT, Brady MF, Homesley HD et al. (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22: 3902–3908

    Article  PubMed  CAS  Google Scholar 

  42. Fleming GF, Filiaci VL, Bentley RC et al. (2004) Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 15: 1173–1178

    Article  PubMed  CAS  Google Scholar 

  43. Fleming GF, Brunetto VL, Cella D et al. (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 2159–2166

    Article  PubMed  CAS  Google Scholar 

  44. Sorbe B, Andersson H, Boman K et al. (2008) Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 18: 803–808

    Article  PubMed  CAS  Google Scholar 

  45. Randall ME, Filiaci VL, Muss H et al. (2006) Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 24: 36–44

    Article  PubMed  CAS  Google Scholar 

  46. Maggi R, Lissoni A, Spina F et al. (2006) Adjuvant chemotherapy vs radiotherapy in highrisk endometrial carcinoma: results of a randomised trial. Br J Cancer 95: 266–271

    Article  PubMed  CAS  Google Scholar 

  47. Susumu N, Sagae S, Udagawa Y et al. (2008) Japanese Gynecologic Oncology Group. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108: 226–233

    Article  PubMed  CAS  Google Scholar 

  48. Oza AM, Elit L, Biagni J, Chapman et al. (2006) Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer. J Clin Oncol 24: 3003

    Google Scholar 

  49. Aghajanian C, Sill MW, Darcy K, Greer B et al. (2009) A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer. A Gynecologic Oncology Group study. J Clin Oncol 27: 5531

    Google Scholar 

  50. Fleming GF, Still MW, Darcy KM et al. (2010) Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 116: 15–20

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de médecine, comité de gynécologie, Institut Gustave Roussy, 114, rue Édouard Vaillant, 94805, Villejuif

    Y. Tazi & S. Gouy

  2. Service de radiothérapie oncologique, Hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l’Hôpital, 75013, Paris

    R. Mazeron

  3. Service de gynécologie, Institut Gustave Roussy, 114, rue Édouard Vaillant, 94805, Villejuif

    P. Pautier

Authors
  1. Y. Tazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Mazeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Gouy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Pautier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Tazi, Y., Mazeron, R., Gouy, S., Pautier, P. (2011). Cancer de l’endomètre. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_32

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_32

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation